Theranostic applications of antibodies in oncology

• Published in: Molecular oncology Vol. 8; no. 4; pp. 799 - 812
• Main Authors: Fleuren, Emmy D.G., Versleijen-Jonkers, Yvonne M.H., Heskamp, Sandra, van Herpen, Carla M.L., Oyen, Wim J.G., van der Graaf, Winette T.A., Boerman, Otto C.
• Format: Journal Article
• Language: English
• Published: United States Elsevier B.V 01.06.2014; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Animals; Antibodies; Antibodies - therapeutic use; Antibody; Antigens; Biomarker; Biomarkers; Cancer therapies; Chemotherapy; Colorectal cancer; Cytotoxicity; Diagnostic tests; Dosimetry; FDA approval; Gene amplification; Humans; Immunoglobulins; Immunohistochemistry - methods; Immunologic Tests - methods; Immunotherapy; Immunotherapy - methods; Kinases; Lymphoma; Medical Oncology - methods; Medical Oncology - trends; Metastasis; Molecular imaging; Molecular Targeted Therapy - methods; Neoplasms - diagnosis; Neoplasms - therapy; Oncology; Patients; Personalized medicine; Precision medicine; Review; Reviews; Theranostics; Tumors; Vascular endothelial growth factor; Molecular imaging; Biomarker; Personalized medicine; Antibody; Theranostics
• ISSN: 1574-7891; 1878-0261
• DOI: 10.1016/j.molonc.2014.03.010

Targeted therapies, including antibodies, are becoming increasingly important in cancer therapy. Important limitations, however, are that not every patient benefits from a specific antibody therapy and that responses could be short-lived due to acquired resistance. In addition, targeted therapies are quite expensive and are not completely devoid of side-effects. This urges the need for accurate patient selection and response monitoring. An important step towards personalizing antibody treatment could be the implementation of theranostics. Antibody theranostics combine the diagnostic and therapeutic potential of an antibody, thereby selecting those patients who are most likely to benefit from antibody treatment. This review focuses on the clinical application of theranostic antibodies in oncology. It provides detailed information concerning the suitability of antibodies for theranostics, the different types of theranostic tests available and summarizes the efficacy of theranostic antibodies used in current clinical practice. Advanced theranostic applications, including radiolabeled antibodies for non-invasive functional imagining, are also addressed. Finally, we discuss the importance of theranostics in the emerging field of personalized medicine and critically evaluate recent data to determine the best way to apply antibody theranostics in the future. •Importance of antibody theranostics in personalizing targeted cancer treatment.•Limitations of conventional theranostic tests.•Advantages of novel, advanced theranostic approaches.•Difference in theranostic applications for conjugated and unconjugated antibodies.